ISRCTN29337285TerminatedPhase 2
A platform study evaluating the efficacy and safety of investigational therapies in participants with chronic hepatitis B infection (PREVAIL)
VIR Biotechnology (United States)0 sites150 target enrollmentStarted: September 28, 2022Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Male or female aged 18 years old and over
- •2. Chronic HBV infection for >/= 6 months
- •3. A Body Mass Index (BMI) less than 18 kg/m2 or greater than 35 kg/m2
Exclusion Criteria
- •1. History or current suspicion of malignancy diagnosed or treated within 5 years
- •2. Any clinically significant medical or psychiatric condition that may interfere with study intervention, assessment, or compliance with the protocol or otherwise makes the participant unsuitable for participation in the study
- •3. History or evidence of drug or alcohol abuse
- •4. History of hepatic decompensation
Investigators
Similar Trials
Active, not recruiting
Phase 1
Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstructioInoperable malignant bowel obstructionMedDRA version: 9.1Level: LLTClassification code 10006055Term: Bowel obstructionEUCTR2009-012981-30-BEniversity Hospital Ghent40
Not yet recruiting
Not Applicable
A Pilot study to Evaluate the Efficacy and Safety of Autologous Adipose tissue-derived Stromal Vascular Fraction(SVF) treatment for the Patients with articular cartilage injury of the kneeKCT0005566Samsung Medical Center3
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.EUCTR2007-004337-41-FRGENFIT30
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind, parallel group, placebo-controlled and randomized study.patients presenting with impaired glucose tolerance and abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10036481Term: Pre-diabetesMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2009-011003-23-FRGENFIT40
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.Atherogenic dyslipidaemic patients with abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10058108Term: DyslipidaemiaMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2008-005779-86-FRGENFIT90